Navigation Links
WuXi PharmaTech Announces Third-Quarter 2013 Results
Date:11/12/2013

inancial results exclude the impact of share-based compensation expenses and the amortization of acquired intangible assets and the associated deferred tax impact. 

Third-quarter 2013 non-GAAP gross profit increased 13.1% year over year to $53.9 million, due to the 16.6% revenue growth, offset by business mix, as the strongest revenue growth was achieved in Manufacturing Services, which has a lower gross margin than Laboratory Services.  Non-GAAP gross margin decreased year over year to 36.7% from 37.8%, mainly due to revenue mix of faster-growing Manufacturing Services revenues with relatively low gross margin and the effects of increasing labor costs in China and appreciation of the RMB versus the U.S. dollar, partially offset by improved productivity and the ramp-up of biologics and preclinical services. 

Third-quarter 2013 non-GAAP operating income increased 17.5% year over year to $31.3 million, primarily due to the 13.1% increase in non-GAAP gross profit.  Operating margin increased to 21.3% from 21.2% due to lower general and administrative expenses as a percentage of revenue, partially offset by lower gross margin.

Third-quarter 2013 non-GAAP net income grew 31.2% year over year to $34.5 million due to the 17.5% increase in non-GAAP operating income, higher other income primarily due to $3.1 million of realized gains and $2.6 million of mark-to-market gains on foreign-exchange forward contracts, higher interest income due to higher cash balances and higher interest rates, and a reduction in the effective tax rate due to the mix of taxable income, partially offset by $1.4 million of equity-method investment losses associated with our joint ventures with PRA and MedImmune.

Third-quarter 2013 non-GAAP diluted earnings per ADS grew 29.3% year over year to $0.47 due to the 31.2% increase in non-GAAP net income, partially offset by a higher number of outstanding ADSs as a result of the exercise of shares under the
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. WuXi PharmaTech Announces Licensing Agreement for Patient-Derived Xenograft Models with Mayo Clinics Center for Individualized Medicine
2. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
3. WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release
4. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
5. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
6. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
7. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
8. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
9. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
10. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
11. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... of the "An Introduction to Medical Device ... 2-3, 2015)" conference to their offering. ... introduction to the regulations and requirements that apply ... highly interactive, using real life examples and state-of- ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... the "New EU Pharmacovigilance Legislation (London, UK - ... The 15 new EU modules concerning Pharmacovigilance ... Pharmacovigilance is conducted in Europe . ... these modules and their requirements, examine how they overlap ...
(Date:9/2/2015)... Sept. 2, 2015  ArmaGen, Inc., a privately ... to treat severe neurological disorders, announced today that ... multi-center Phase 1/2a clinical trial of AGT-181 in ... AGT-181 is an investigational enzyme ... I. The most severe form of MPS I, ...
Breaking Medicine Technology:An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4
... 18 New data evaluating the impact of screening ... prostate cancer screening. The Prostate Conditions Education Council ... a leader in prostate cancer screening, announced today that ... from two studies, including the preliminary data from the ...
... Platform Designed for Radial Strength, FlexibilityHOUSTON, March 18 ... in the development and marketing of minimally invasive ... Drug Administration (FDA) has approved an investigational device ... its SUPERA stent, a novel stent platform designed ...
Cached Medicine Technology:Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data 2Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data 3U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies' SUPERA Peripheral Stent 2
(Date:9/3/2015)... ... September 03, 2015 , ... The ... Clinicians Report of Provo, Utah. The Clinicians Report is a leading information source ... dentists located throughout the U.S. Whiter Image's In-Office whitening kits were favorably validated ...
(Date:9/3/2015)... ... September 03, 2015 , ... At Renew Man™, we ... with the traditional health care model, where the primary care physician dictates and the ... want to become educated about their health issues and empowered to choose their own ...
(Date:9/3/2015)... ... ... When looking at the types of people who have a hard time gaining weight ... a weak appetite or those that have a fast metabolism. In order to help those ... gives three tips for slowing down metabolism. , The first thing to do is to ...
(Date:9/3/2015)... Rosa, CA (PRWEB) , ... September 03, 2015 , ... About 220,800 new cases of ... One in seven men will be diagnosed with prostate cancer during their lifetime. While only ... to six of every 10 men by age 65, according to the American Cancer ...
(Date:9/3/2015)... , ... September 03, 2015 , ... Local filmmakers and ... Hannah & Michael Habernig from Path 11 Productions have had great success in launching ... podcast has featured Hay House authors, Teal Swan who is the well known Spiritual ...
Breaking Medicine News(10 mins):Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3
... ... ... , ... , , , ...
... ... this weekend, taking the Olympic Gold Medal at the 2010 Vancouver Winter Olympics, bringing SpiderTech, ... ... World Champion USA1 4-man Bobsled team, steamed to new heights this weekend, taking the Olympic ...
... ... Marathon des Sables, a 250km (155 miles) race across the Sahara desert this April 2010. Gary ... , ... The Marathon des Sables will cover 250km/155 miles (in sections approximate to 25, 34, 38, 82, ...
... DC, USA Today, during the 39th Annual ... convening at the Walter E. Washington Convention Center ... Ohio State University, will present a poster of ... Modulation Facilitating Oral-Squamous-Cell Carcinoma Progression." Tong and a ...
... ... ... ... ...
... link between breathing in dirty air and heart problems ... to the air pollution particles caused by traffic has ... researchers say. , In the new report, researchers analyzed ... who were assessed every four years between 1995 and ...
Cached Medicine News:Health News:Christiana Care Health System Wins National Award for Innovation 2Health News:Christiana Care Health System Wins National Award for Innovation 3Health News:SpiderTech Rides the Night Train to Olympic Gold 2Health News:SpiderTech Rides the Night Train to Olympic Gold 3Health News:SpiderTech Rides the Night Train to Olympic Gold 4Health News:Mt. Everest Summiter Gary Guller (With One Arm) To Race Across Sahara in "The World's Toughest Stage Race" 2Health News:Mt. Everest Summiter Gary Guller (With One Arm) To Race Across Sahara in "The World's Toughest Stage Race" 3Health News:MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD 2Health News:MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD 3Health News:MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD 4Health News:MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD 5Health News:Years of Exposure to Traffic Pollution Raises Blood Pressure 2
Intermittent catheter...
Intermittent catheter...
Intermittent catheter...
Disease diagnosis and treatment reference sourced from Griffith's 5-Minute Clinical Consult. Save time diagnosing and treating more than 1,200 diseases and conditions....
Medicine Products: